FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Исследования/Highlighting the comparative effectiveness and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in patients with overweight or obesity.
Назад в Научную Библиотеку
GLP-1 receptor agonistsdual agonistsretatrutide

Highlighting the comparative effectiveness and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in patients with overweight or obesity.

May 16, 2026
Share

Исходная статья

Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.

Sinha Binayak et al.Obesity (Silver Spring, Md.)2025
Развивающиеся Исследования

Основано на развивающихся исследованиях. Эти выводы обещающи, но требуют дальнейшей проверки.

О данном анализе

Эта статья разбивает выводы из исходной статьи выше на доступный язык для сообщества исследований Peptide. Наша цель — подчеркнуть то, что наиболее важно — практические последствия, надежность доказательств и то, что это означает для текущих исследований.

New Insights into Weight Loss Therapies: GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide

Published: May 16, 2026 | Source: Obesity (Silver Spring, Md.) (2025) | Category: GLP-1 receptor agonists, dual agonists, retatrutide

Overview

A recent study published in Obesity offers a comprehensive comparison of the efficacy and safety profiles of GLP-1 receptor agonists (GLP-1RAs), dual agonists, and retatrutide for weight loss among adults with overweight or obesity. The findings suggest that while these therapies are effective, they come with varying levels of risk and benefits depending on patient characteristics.

Study Background

Previous research has highlighted the potential of GLP-1 receptor agonists in aiding weight management, but there was a need to understand how newer agents like dual agonists and retatrutide compare. This study aimed to fill that gap by conducting a Bayesian network meta-analysis (NMA) to evaluate these treatments comprehensively.

What the Research Found

The analysis included 19 randomized controlled trials involving over 29,500 participants with BMI ≥ 25 kg/m². The results showed that retatrutide and dual agonists achieved a mean weight loss of -11.0 kg, surpassing GLP-1RAs at -9.0 kg. Retatrutide was particularly effective in achieving ≥ 15% weight loss, with an odds ratio (OR) of 54.6 compared to GLP-1RAs and dual agonists at ORs of 16.4 and 9.0 respectively.

However, retatrutide also had the highest adverse event risk among the three types of treatments. The study further noted that type 2 diabetes mellitus (T2DM) reduced weight loss efficacy for both GLP-1RAs and dual agonists by approximately 5 kg on average. Additionally, female-dominant or high-BMI cohorts showed enhanced outcomes with these therapies.

What This Means for Peptide Users

For patients considering peptide therapy for weight management, the study provides valuable insights into the comparative benefits and risks of different treatment options. Retatrutide offers superior efficacy but comes with a higher risk of adverse events, making it less suitable for all patient profiles. Dual agonists appear to offer a balanced approach between effectiveness and safety.

Limitations and Caveats

The study acknowledges several limitations, including potential publication bias and heterogeneity among the included trials. The impact of T2DM on treatment efficacy also complicates the interpretation of results, suggesting that personalized treatment selection based on patient characteristics is crucial.

How This Compares to Previous Research

While previous studies have highlighted the effectiveness of GLP-1RAs for weight loss, this study provides a more nuanced comparison by including dual agonists and retatrutide. The findings align with earlier research in terms of efficacy but offer new insights into safety profiles and patient-specific outcomes.

Our Analysis

PeptideVault's critical assessment suggests that while the study offers valuable comparative data on GLP-1RAs, dual agonists, and retatrutide, its limitations must be considered. The high adverse event risk associated with retatrutide underscores the importance of personalized treatment approaches in clinical practice.

Key Takeaways

  • Retatrutide is highly effective for weight loss but carries a higher risk of adverse events.
  • Dual agonists provide an optimal balance between efficacy and safety, making them suitable for broader patient profiles.
  • Personalized treatment selection based on individual characteristics such as T2DM status and BMI is recommended.

Original Source

Citation: Sinha Binayak, Ghosal Samit (2025). Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.. Obesity (Silver Spring, Md.). DOI: 10.1002/oby.24360

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Примечание Редактора

Этот анализ был подготовлен командой исследований Peptide Contacts. Мы призываем читателей проверить полный исходный источник полная методология и данные. Исходное издание доступно на PubMed.

Связанные Исследования

Comments

Sign in to join the discussion

Этот анализ сгенерирован на основе рецензированных исследований для образовательных целей только. Это не является медицинским советом. Всегда консультируйтесь с квалифицированным медицинским специалистом перед использованием каких-либо терапий на основе Peptide.